

Key data to be presented at ASH 2024

Haemophilia A		
Altuvoct® (efanesoctocog alfa)	Association Between Hemophilia Joint Health Score and Quality of Life Using Results from the XTEND-1 Efanesoctocog Alfa Phase 3 Trial	Oral presentation. Session: 322 Session date: Monday, December 9, 2024, 10:30 AM - 12:00 PM Presentation time: 11:30 AM
	Clinical Outcomes Over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study	Oral presentation. Session: 322. Session date: Monday, December 9, 2024, 10:30 AM - 12:00 PM Presentation time: 11:00 AM
	Real-world Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate or Severe Hemophilia A: An Analysis of the Adelphi Hemophilia Disease Specific Programme™	Oral presentation. Session: 322 Session date: Saturday, December 7, 2024, 12:00 PM - 1:30 PM Presentation Time: 1:00 PM
	Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia A	Poster presentation. Session: 322 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM
General haemophilia A		
	Unmet Needs, Factor Consumption, and Healthcare Resource Use among People with Hemophilia A: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme™	Poster presentation. Session: 721 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM
	Real-World Patterns of Additional Factor Treatment Use Among Hemophilia A Patients on Regular Prophylaxis in the United States: Results from the PicnicHealth database	Poster presentation. Session: 721 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM
Haemophagocytic Lymphohistiocytosis		

Gamifant® (emapalumab)	Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab as a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study	Poster presentation.Session: 721 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM
	Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment	Poster presentation.Session: 201 Session date: Monday, December 9, 2024 Presentation time: 6:00 PM - 8:00 PM

Myelofibrosis

Vonjo® (pacritinib)	Hematologic Improvement Experienced by Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings	Poster presentation.Session: 908 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM
	Improvement in Serum Albumin as a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: a Retrospective Analysis of Patients Treated Across Three Clinical Trials	Poster presentation.Session: 634 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM

Paroxysmal Nocturnal Haemoglobinuria

Aspaveli®/Empaveli® (pegcetacoplan)	Real-World Clinical Outcomes for Complement inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada	Poster presentation.Session: 905 Session date: Monday, December 9, 2024 Presentation time: 6:00 PM - 8:00 PM
-------------------------------------	--	--

Immune Thrombocytopenia

Doptelet® (avatrombopag)	Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 ADOPT Study	Oral presentation. Session: 311 Session date: Monday, December 9, 2024, 10:30 AM - 12:00 PM Presentation time: 11:45 AM
	Analysis of Durability of Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Patients with Immune Thrombocytopenia	Poster presentation. Session: 311 Session date: Saturday, December 7, 2024, Presentation time: 5:30 PM - 7:30 PM
	Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or	Poster presentation. Session: 311

<p>Romiplostim (ROMI) to Avatrombopag (AVA) In Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-hoc Analyses from a Prospective Phase 4 Study</p>	<p>Session date: Saturday, December 7, 2024, Presentation time: 5:30 PM - 7:30 PM</p>
<p>Results of a Prospective, Open-label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag (AVA) from Eltrombopag (ELT) or Romiplostim (ROMI)</p>	<p>Poster presentation. Session: 311 Session date: Saturday, December 7, 2024, Presentation time: 5:30 PM - 7:30 PM</p>
<p>Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim</p>	<p>Poster presentation. Session: 905 Session date: Sunday, December 8, 2024 Presentation time: 6:00 PM - 8:00 PM</p>